Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 3Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Recurrence 1Neuroendocrine Tumors 1Lymphoma, Mantle-Cell 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 3Erlotinib Hydrochloride 3surufatinib 2gallium Ga 68 dotatate 2dactolisib 2Sunitinib 2Magnetic Resonance Spectroscopy 2trifluridine tipiracil drug combination 1tislelizumab 1telotristat ethyl 1telotristat 1pertuzumab 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1lanreotide 1fosbretabulin 1entinostat 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1alectinib 1Temozolomide 1Surveys and Questionnaires 1Somatostatin 1Serotonin 1Quality of Life 1Positron Emission Tomography Computed Tomography 1Panobinostat 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neuroendocrine Tumors × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT03724409 2023-11-28

Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

University of Iowa

Phase EARLY_PHASE1 Terminated
3 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡